Envestnet Portfolio Solutions Inc. Boosts Stake in Eli Lilly and Company $LLY

Posted by Francis Steltz on Sep 23rd, 2026

Eli Lilly and Company logo Envestnet Portfolio Solutions Inc. increased its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 7.7% during the second quarter, HoldingsChannel reports. The fund owned 41,689 shares of the company’s stock after buying an additional 2,976 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Eli Lilly and Company were worth $49,991,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. State Street Corp increased its holdings in shares of Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares in the last quarter. Capital World Investors lifted its stake in shares of Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after purchasing an additional 61,851 shares during the period. Norges Bank purchased a new stake in Eli Lilly and Company during the fourth quarter worth about $12,976,634,000. Finally, Bank of America Corp DE purchased a new stake in Eli Lilly and Company during the second quarter worth about $13,522,666,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on LLY shares. HSBC increased their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. Royal Bank Of Canada boosted their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 8th. UBS Group set a $1,376.00 price target on Eli Lilly and Company in a report on Friday, August 7th. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $1,419.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,305.25.

Read Our Latest Report on LLY

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $16.45 on Wednesday, hitting $1,153.69. The company’s stock had a trading volume of 2,153,958 shares, compared to its average volume of 3,016,686. Eli Lilly and Company has a 12-month low of $712.05 and a 12-month high of $1,292.65. The company has a market capitalization of $1.09 trillion, a price-to-earnings ratio of 38.71, a price-to-earnings-growth ratio of 1.44 and a beta of 0.50. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The stock has a 50 day moving average of $1,176.84 and a 200-day moving average of $1,079.50.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same period last year, the company posted $6.31 EPS. The company’s revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts predict that Eli Lilly and Company will post 36.54 EPS for the current year.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: CEO Dave Ricks said Lilly is capturing about 70% of new senior GLP-1 patients following Medicare coverage expansion, while oral GLP-1 drug Foundayo accounts for roughly one-third of new oral-treatment starts. The comments reinforce Lilly’s commercial leadership and suggest that expanded insurance coverage could materially enlarge the addressable market. Lilly CEO discusses Medicare GLP-1 market share
Positive Sentiment: Lilly broke ground on a $6.5 billion Houston manufacturing facility that will produce active ingredients for Foundayo and other medicines. The investment supports the company’s planned oral GLP-1 rollout, strengthens domestic supply, and is expected to create more than 600 jobs, although the benefits will take time to materialize. Lilly Houston manufacturing facility
Positive Sentiment: Investors remain bullish on Lilly’s long-term growth. Home Depot co-founder Ken Langone said the shares could reach $2,000 within three to four years, reflecting confidence in the company’s obesity portfolio and broader pipeline. Ken Langone bullish on Lilly
Neutral Sentiment: Lilly received full FDA approval for Inluriyo in combination with Verzenio for advanced ESR1-mutated breast cancer, adding support to its oncology franchise. The approval is strategically positive but likely less important to near-term valuation than the obesity business. Inluriyo FDA approval
Negative Sentiment: Viking Therapeutics reported data indicating its VK2735 obesity drug preserved most weight loss with every-other-week or monthly dosing. The result drove strong interest in a potential competitor to Zepbound, raising concerns about future pricing, adherence, and market-share pressure for Lilly, although Viking still needs Phase 3 results and regulatory approval. Viking obesity drug maintenance data
Negative Sentiment: Novo Nordisk’s CagriSema also produced favorable late-stage weight-loss data in a diabetes study, keeping competitive pressure high. Lilly’s $6.5 billion facility further increases near-term capital spending, which may temper enthusiasm despite strong long-term demand.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by insiders.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.